RIDE-001 / Trained Therapeutix Discovery - LARVOL DELTA

Trained Therapeutix Demonstrates RIDE-001 Trains Myeloid Cells for Anti-Tumor Immune Response in Preclinical Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) - "The data demonstrated that RIDE-001 effectively induced trained immunity in vitro in primary human immune cells, induced anti-tumor immunity in mouse tumor models of melanoma and colorectal cancer, and safely induced innate immune responses in rats and non-human primates. RIDE-001 showed therapeutic activity against solid tumors as a single agent, and it also exhibited synergy in combination with immune checkpoint inhibition."

Preclinical • Colorectal Cancer • Melanoma

RIDE-001: A well-tolerated innate immunotherapy to treat cancer by targeting and reprogramming bone marrow progenitor cells (SITC 2025) - "Spurred by its excellent safety profile, Trained Therapeutix has initiated GMP manufacturing of RIDE-001 in anticipation of the first clinical studies in patients with solid tumors. Its successful clinical development is a potential breakthrough for cancer patients who do not benefit from checkpoint inhibition due to myeloid-driven immunosuppression."

Colorectal Cancer • Melanoma • Oncology • Solid Tumor • APOA1